Clinica chimica acta; international journal of clinical chemistry · 2025
Early serum PreS1 levels are predictive of HBsAg loss in interferon-alpha treated children with HBeAg-positive chronic hepatitis B.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Fan Peiyao, Wang Fuchuan, Dong Yi, Yan Jianguo, Cao Lili, Gao Yinjie, Xu Zhiqiang, Zhong Yanwei, Zhang Min
Аннотация
BACKGROUND AND AIM(S): The PreS1 surface antigen of large surface proteins (LHBs) plays an important role in predicting clinical outcomes in adults with chronic hepatitis B (CHB). This study aimed to determine whether PreS1 levels can predict HBsAg loss in children with HBeAg-positive CHB undergoing a 48-week interferon-alpha (IFN-α) therapy protocol.
METHODS: We conducted a retrospective analysis of 133 children with CHB. Biomarkers and clinical outcomes were assessed every three months. The area under the receiver operating characteristic (AUROC) curve was calculated to evaluate the predictive value of different biomarkers for HBsAg loss at the 48-week end-point.
RESULTS: At the end of the 48-week IFN-α therapy, HBsAg loss was achieved in 16.5 % (22/133) of patients. PreS1 levels were positively correlated with serum quantitative HBsAg (qHBsAg) and hepatitis B virus (HBV) DNA levels. At baseline, only the PreS1/qHBsAg ratio predicted HBsAg loss at week 48 (AUROC = 0.661, p = 0.015). At week 12, PreS1 levels also predicted HBsAg loss at week 48 (AUROC = 0.875, p < 0.001).
CONCLUSIONS: Early serum PreS1 levels and the PreS1/qHBsAg ratio may serve as useful predictors of HBsAg loss in children with CHB receiving IFN-α therapy, providing potential guidance for clinical decision-making.
METHODS: We conducted a retrospective analysis of 133 children with CHB. Biomarkers and clinical outcomes were assessed every three months. The area under the receiver operating characteristic (AUROC) curve was calculated to evaluate the predictive value of different biomarkers for HBsAg loss at the 48-week end-point.
RESULTS: At the end of the 48-week IFN-α therapy, HBsAg loss was achieved in 16.5 % (22/133) of patients. PreS1 levels were positively correlated with serum quantitative HBsAg (qHBsAg) and hepatitis B virus (HBV) DNA levels. At baseline, only the PreS1/qHBsAg ratio predicted HBsAg loss at week 48 (AUROC = 0.661, p = 0.015). At week 12, PreS1 levels also predicted HBsAg loss at week 48 (AUROC = 0.875, p < 0.001).
CONCLUSIONS: Early serum PreS1 levels and the PreS1/qHBsAg ratio may serve as useful predictors of HBsAg loss in children with CHB receiving IFN-α therapy, providing potential guidance for clinical decision-making.